Leslie Smith, DNP, discusses mediating trial care, vetting protocols for nursing scope of practice, and guiding frontline nurses toward research.
|Videos|September 12, 2016
Tim & Meghan: A Survivor’s Journey
Author(s)Melanoma Foundation of New England
Advertisement
Both Tim and Meghan have had first hand experiences with melanoma, the deadliest form of skin cancer. Walk through their journeys with them as they tell their stories.
Advertisement
Related to this article
Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
Long-term QUILT-3.032 data in BCG-unresponsive NMIBC with CIS show durable responses for some patients and a long, surveillance-heavy course.
The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.
Discover how equine-assisted services support patients with cancer by improving emotional wellness, building confidence, and enhancing quality of life.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Tucatinib Maintenance for HER2+ Breast Cancer: What Nurses, PAs Should Know
2
Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years
3
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
4
Patient Safety First: How a CNS Bridges Oncology Research and the Bedside
5